Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-344 vs Lixiana in Healthy Volunteers
NCT04867200Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-344 in thromboembolism (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under Curve last at 48 hours and Maximum Plasma Concentration at 48 hours. Status: unknown.
02
Drugs
CKD-344
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04867200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867200.